Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia

A technology of thrombocytopenia and icariin, which is applied in the field of medicine, can solve the problems of unsustainable therapeutic effect and easy recurrence of side effects, and achieve the effects of increasing medication compliance, low drug side effects, and definite curative effect

Active Publication Date: 2015-04-29
LUNAN PHARMA GROUP CORPORATION
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In order to overcome the technical deficiencies in the prior art that the treatment effect of the medicine for thrombocytopenia is not long-lasting, the drug is easy to relapse and the side effects are large, the present invention provides a medicine for the treatment of thrombocytopenia, which uses icarigenin as the main active ingredient , when it is used in the treatment of thrombocytopenia, it has the characteristics of definite curative effect, small side effects, and no rebound after drug withdrawal, and is very suitable for clinical use in patients with thrombocytopenia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia
  • Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia
  • Application of anhydroicaritin in preparing drug for treating or preventing thrombopenia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Icarigenin Injection

[0022] prescription:

[0023] Icarigenin 10mg

[0024] Propylene glycol 3ml

[0025] Ethanol 0.5ml

[0026] Add 0.9% sodium chloride solution to 10ml

[0027] ____________

[0028] Preparation Process:

[0029] Mix the prescribed amount of propylene glycol and ethanol evenly, add icariin, stir to dissolve, add the prescribed amount of 0.9% sodium chloride solution, stir evenly, add 0.5% activated carbon for needles, stir, and decarbonize to obtain the product.

Embodiment 2

[0030] Example 2 Icarigenin Injection

[0031] prescription:

[0032] Icarigenin 10mg

[0033] PEG-400 2ml

[0034] Add 0.9% sodium chloride solution to 10ml

[0035] __________

[0036] Preparation process: add the prescribed amount of PEG-400 to icariin, stir to dissolve, add 0.9% sodium chloride solution to 10ml, stir evenly, add 0.5% activated carbon for needles, stir, and decarbonize to obtain the product.

Embodiment 3

[0037] Example 3 Icarigenin Injection

[0038] prescription:

[0039] Icariin 50mg

[0040] Ethanol 3.5ml

[0041] Tween-80 1.5g

[0042] Add water for injection to 10ml

[0043] Preparation process: Mix the prescribed amount of ethanol and Tween-80 evenly, add icariin, stir to dissolve, add 0.9% sodium chloride solution to 10ml, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize , that is.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel medical application of anhydroicaritin, particularly to application of anhydroicaritin in preparing a drug for treating or preventing thrombopenia, and belongs to the field of medicines. In order to overcome the technical defects that, in the prior art, the thrombopenia therapeutic drug is unabiding in therapeutic effect, high in possibility of recidivation during drug discontinuance and high in side effect, the invention provides a therapeutic drug containing anhydroicaritin. The therapeutic drug can greatly improve the platelet level of a parent when being used for treating thrombopenia, particularly immune thrombopenia, and has an obvious therapeutic effect; the therapeutic drug further has the obvious therapeutic effect on treating thrombopenia caused by myelosuppression; when being used for treating thrombopenia, anhydroicaritin has the advantages of being obvious in curative effect, low in treatment cost and little in toxic and side effects, and the therapeutic drug is quite suitable for clinical popularization and application.

Description

technical field [0001] The invention relates to a new medical application of icariin, in particular to the application of icariin in the preparation of medicines for treating or preventing thrombocytopenia, and belongs to the field of medicine. Background technique [0002] Thrombocytopenia is a disease caused by decreased platelets in peripheral blood (<100,000 / μl) leading to bleeding in the skin, mucous membranes and internal organs. Violet blood blisters on the mucous membrane and tongue are common clinical diseases characterized by coagulation dysfunction and bleeding. Severe cases can cause massive hemorrhage, which is life-threatening. It accounts for about 30% of bleeding diseases in clinical practice. [0003] The causes of thrombocytopenia can be divided into: (1) Decreased or ineffective death of platelet production: including hereditary and acquired. Acquired thrombocytopenia is caused by certain factors such as drugs, malignant tumors, infections, ionizing rad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P7/04
CPCA61K31/352
Inventor 赵志全李涛李光艳孙成宏
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com